Esperion Therapeutics Inc. ESPR
Super Investor & Insider
Nessuna transazione insider negli ultimi 6 mesi.
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Esperion Therapeutics Inc. is a pharmaceutical company that develops and commercializes oral, once-daily, non-statin medicines designed for patients with elevated low-density lipoprotein cholesterol. The company's primary marketed products are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe), which…
SectorHealthcare
ExchangeNASDAQ
IndustryDrug Manufacturers - Specialty & Generic
CountryUnited States
Employees294
TickerESPR
Statistics
Market Cap$812.1M
Revenue (TTM)$403.1M
Net Income-$22.7M
Net Margin-5.6%
EPS$-0.11
P/E-28.59
P/S1.94
P/B-2.57
EV/EBITDA15.76
ROE7.5%
Dividend Yield—
Price$3.15
Data: Twelve Data · Revenue = mcap / P/S